James P. Allison

Research interests

Publications

• Immune checkpoint therapy—current perspectives and future directions

  Cell · 2023 · 10.1016/j.cell.2023.03.006

• Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

  Nature Medicine · 2021 · 10.1038/s41591-020-01224-2

• Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

  Science · 2021 · https://doi.org/10.1126/science.aaz7015

• The Next Decade of Immune Checkpoint Therapy

  Cancer Discovery · 2021 · https://doi.org/10.1158/2159-8290.cd-20-1680

• Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

  Nature Medicine · 2018 · https://doi.org/10.1038/s41591-018-0238-9

• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-0367

• VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

  Nature Medicine · 2017 · 10.1038/nm.4308

• Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

  Science · 2017 · https://doi.org/10.1126/science.aan4236

• Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

  Science Translational Medicine · 2017 · 10.1126/scitranslmed.aah3560

• Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

  Cell · 2017 · 10.1016/j.cell.2017.07.024

• Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

  Nature Communications · 2016 · 10.1038/ncomms12632

• Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

  Cell · 2016 · 10.1016/j.cell.2016.08.069

• Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

  Cancer Discovery · 2016 · 10.1158/2159-8290.cd-15-1545

• The future of immune checkpoint therapy

  Science · 2015 · https://doi.org/10.1126/science.aaa8172

• Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

  Cancer Discovery · 2015 · 10.1158/2159-8290.cd-14-1236

• Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

  Cell · 2015 · 10.1016/j.cell.2015.03.030

• Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

  Nature · 2014 · 10.1038/nature13988

• Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

  Cancer Cell · 2014 · 10.1016/j.ccr.2014.04.005

• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

  The Journal of Experimental Medicine · 2013 · 10.1084/jem.20130579

• Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

  Nature · 2012 · 10.1038/nature10755

• Cancer classification using the Immunoscore: a worldwide task force

  Journal of Translational Medicine · 2012 · 10.1186/1479-5876-10-205

• Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1112824

• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  Proceedings of the National Academy of Sciences · 2010 · 10.1073/pnas.0915174107

• The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

  Clinical Cancer Research · 2009 · 10.1158/1078-0432.ccr-09-0737

• Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer

  Clinical Cancer Research · 2005 · 10.1158/1078-0432.728.11.2

• Restoring function in exhausted CD8 T cells during chronic viral infection

  Nature · 2005 · https://doi.org/10.1038/nature04444

• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  Proceedings of the National Academy of Sciences · 2003 · 10.1073/pnas.1533209100

• Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

  The Journal of Experimental Medicine · 2001 · 10.1084/jem.194.6.823

• Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

  The Journal of Experimental Medicine · 1999 · 10.1084/jem.190.3.355

• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  Science · 1996 · https://doi.org/10.1126/science.271.5256.1734

• CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

  The Journal of Experimental Medicine · 1995 · 10.1084/jem.182.2.459

• Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells

  Science · 1993 · 10.1126/science.7678351

• CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

  Nature · 1992 · 10.1038/356607a0

Current projects

No projects listed.